Loading…
Zenas BioPharma, Inc. is projected to rise to $28.39 by 2027, a +57% move from its current price of $18.09. ZBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $17.34 | $18.10 | $18.89 | +0.05% |
| May 30 | $17.05 | $18.11 | $19.23 | +0.10% |
| May 31 | $16.82 | $18.12 | $19.51 | +0.15% |
| Jun 1 | $16.64 | $18.12 | $19.74 | +0.19% |
| Jun 2 | $16.48 | $18.13 | $19.95 | +0.24% |
| Jun 3 | $16.34 | $18.14 | $20.14 | +0.29% |
| Jun 4 | $16.21 | $18.15 | $20.32 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.21 | $18.15 | $20.32 | +0.34% |
| Week 2 | $15.52 | $18.21 | $21.37 | +0.68% |
| Week 3 | $15.03 | $18.27 | $22.22 | +1.02% |
| Week 4 | $14.63 | $18.34 | $22.99 | +1.36% |
| Week 5 | $14.29 | $18.40 | $23.69 | +1.71% |
| Week 6 | $14.00 | $18.46 | $24.35 | +2.05% |
| Week 7 | $13.74 | $18.52 | $24.98 | +2.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zenas BioPharma, Inc. is a clinical-stage biopharma company that develops transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company also develops ZB002, ZB004, and ZB001.
The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. It was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Zenas BioPharma, Inc. (ZBIO) trades at $18.97 per share. Its market capitalization is $1.2B and its market rank is 2393.
The 2026–2050 forecast shows a path of growth, with 2026 average price $18.97, then rising to 2027 average $30.00 and 2030 average $35.61, reaching $154.58 on average by 2050. These forecasts include a range of values and related ROI figures, indicating potential upside over time.
A major floor 22.4% below — a decisive break under it would weaken the trend.
The nearest floor, 6.5% below — buyers have tended to step in here.
The nearest ceiling, 20.6% above — a clean break opens room to run.
A major ceiling 49.4% above — clearing it would confirm fresh momentum.
Key ZBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.04 | Sell | $18.65 | Sell |
| MA 10 | $18.71 | Sell | $18.83 | Sell |
| MA 20 | $19.25 | Sell | $19.18 | Sell |
| MA 50 | $20.20 | Sell | $20.43 | Sell |
| MA 100 | $21.45 | Sell | $21.99 | Sell |
| MA 200 | $24.55 | Sell | $21.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.56 | Neutral |
| Stoch RSI (14) | 48.09 | Neutral |
| CCI (20) | -88.31 | Neutral |
| Williams %R (14) | -66.19 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -7.89 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 33.81 | Neutral |
| TRIX (15) | -0.37 | Sell |
| Awesome (5,34) | -0.62 | Sell |
| Ultimate (7,14,28) | 44.50 | Neutral |
| Momentum (10) | -1.07 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 19.05 | Sell |
| ADX (14) | 11.39 | Neutral |
| ATR (14) | 0.81 | Info |
The near-term technical picture is bullish. RSI(14) is 50, with prices trading around key moving averages.
Key levels include a 50-day simple moving average of $20.41 and a 200-day simple moving average of $24.51, with nearby support at $16.91 and resistance at $21.82. The 30-day price range runs from $14.13 to $25.47, and annualized volatility is 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.20 | $18.09 | $27.90 | 0% | Neutral | |
| $21.29 | $28.39 | $40.74 | +57% | Bullish | |
| $20.57 | $28.71 | $43.38 | +59% | Bullish | |
| $19.97 | $28.97 | $45.56 | +60% | Bullish | |
| $22.72 | $34.12 | $55.50 | +89% | Bullish | |
| $20.86 | $32.36 | $54.19 | +79% | Bullish | |
| $25.37 | $40.56 | $69.73 | +124% | Bullish | |
| $33.26 | $54.74 | $96.34 | +203% | Bullish | |
| $32.33 | $54.72 | $98.39 | +202% | Bullish | |
| $32.19 | $55.97 | $102.66 | +209% | Bullish | |
| $45.09 | $89.08 | $177.41 | +392% | Bullish | |
| $67.93 | $150.95 | $338.05 | +734% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $15.20 | $18.09 | $21.46 | +0.00% |
| June 2026 | $15.95 | $18.97 | $23.26 | +4.84% |
| July 2026 | $15.69 | $18.90 | $23.66 | -0.32% |
| August 2026 | $15.16 | $18.46 | $23.47 | -2.37% |
| September 2026 | $15.86 | $19.49 | $25.09 | +5.57% |
| October 2026 | $16.81 | $20.81 | $27.11 | +6.81% |
| November 2026 | $16.66 | $20.78 | $27.34 | -0.16% |
| December 2026 | $16.73 | $21.01 | $27.90 | +1.10% |
Click any year to see its month-by-month ZBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ZBIO is projected to trade between $15.20 and $27.90, averaging $18.09 — a potential gain of 0% from today's $18.09. A consolidation phase looks the most probable path here.
Zenas BioPharma, Inc.'s 2027 outlook centres on $28.39, within a $21.29 to $40.74 range. That is up +57% on the projected 2026 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2028, ZBIO could reach as high as $43.38, with a base case around $28.71 and support toward $20.57 — roughly +59% from $18.09. Buyers look set to stay in control over this stretch.
Expect ZBIO to range from $19.97 to $45.56 through 2029. The $28.97 average target implies a +60% move from current prices. That is up +1% on the projected 2028 average. Momentum favours further upside here.
The ZBIO price prediction for 2030 points to an average of $34.12 (low $22.72, high $55.50) — a potential gain of +89% on today's $18.09. Buyers look set to stay in control over this stretch.
In 2031, ZBIO is projected to trade between $20.86 and $54.19, averaging $32.36 — a potential gain of +79% from today's $18.09. That is -5% versus the projected 2030 average. Momentum favours further upside here.
Zenas BioPharma, Inc.'s 2032 outlook centres on $40.56, within a $25.37 to $69.73 range. That is up +25% on the projected 2031 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ZBIO could reach as high as $96.34, with a base case around $54.74 and support toward $33.26 — roughly +203% from $18.09. Momentum favours further upside here.
Expect ZBIO to range from $32.33 to $98.39 through 2034. The $54.72 average target implies a +202% move from current prices. That is 0% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The ZBIO price prediction for 2035 points to an average of $55.97 (low $32.19, high $102.66) — a potential gain of +209% on today's $18.09. Momentum favours further upside here.
In 2040, ZBIO is projected to trade between $45.09 and $177.41, averaging $89.08 — a potential gain of +392% from today's $18.09. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Zenas BioPharma, Inc.'s 2050 outlook centres on $150.95, within a $67.93 to $338.05 range. That is up +69% on the projected 2040 average. That marks a +734% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ZBIO today (≈ 55.27916 ZBIO) could be worth
$8,344.66
+$7,344.66 (+734%) by 2050 · US Dollar
Based on the average projected ZBIO price of $150.95 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZBIOwould be worth at today's price.
$1,000 invested in ZBIO on May 27, 2025 (≈ 94.696966 ZBIO) would be worth
$1,713.07
+$713.07 (+71.3%) today · 1.71× · US Dollar
Based on a ZBIO entry price of $10.56 vs. today's $18.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.56 | $924.85 | -7.5% |
| 1 month ago | $18.59 | $973.1 | -2.7% |
| 3 months ago | $26.36 | $686.27 | -31.4% |
| 6 months ago | $38.83 | $465.88 | -53.4% |
| 1 year ago | $10.56 | $1,713.07 | +71.3% |
| All time (1.7y) ago | $18.15 | $996.69 | -0.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZBIO forecast.
Our base-case forecast reaches $36.00 around 2032.
Implied market cap at $36.00: $2.27B
The multi-year forecast shows a trajectory of rising averages and sizable upside. For 2026 the average price is $18.97 with a min of $15.20 and a max of $29.77 and 0% ROI; sentiment is Neutral. From 2027 onward the model projects bullish sentiment, with 2027 average $30.00 and 58.1% ROI, and 2028 average $29.94 with 57.8% ROI.
By 2030 the average is $35.61 with 87.7% ROI, and 2031–2035 continue to rise toward higher levels; for example 2032 average $42.19 (122.4% ROI), 2033 $57.39 (202.5%), 2034 $56.22 (196.3%), and 2035 $57.80 (204.7%). The long-range horizon pushes toward $90.77 average in 2040 (378.5% ROI) and $154.58 average in 2050 (714.9% ROI), with bullish sentiment.
These figures are forecasts and not guarantees. They depend on market conditions and other factors not specified here.
Tap a question to reveal the answer.
2030: min $23.36, avg $35.61, max $58.72; ROI 87.7%; sentiment BULLISH.
Forecasts show Neutral in 2026 (avg $18.97, ROI 0) but bullish sentiment in later years, with 2027 avg $30.00 (ROI 58.1%), 2040 avg $90.77 (ROI 378.5%), and 2050 avg $154.58 (ROI 714.9%).
Yes, based on maximum forecast values, the price could exceed $200 by 2050 (max $353.93). Earlier years cap near $102.62–$107.85 by 2033–2035, with $184.30 max in 2040.
Current price is $18.97 per share and market capitalization is $1.2B; market rank is 2393.
RSI(14) is 50; SMA50 is $20.41; SMA200 is $24.51; support is $16.91; resistance is $21.82; 30-day range is $14.13 to $25.47; annualized volatility is 90%.
Zenas BioPharma, Inc. Community Discussion
0Share your Zenas BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.